TABLE 3.
Linear evaluation of plasma pharmacokinetic parameters after single and multiple oral administration of 0.5–18 mg tunlametinib capsule in patients.
| Occasion | Analyte | PK parameters | Point estimate of beta | 90% CI of beta | Beta criteria |
|---|---|---|---|---|---|
| Single dose | Tunlametinib | AUC0-12h | 1.116 | (1.023,1.210) | (0.938,1.062) |
| AUCinf | 1.003 | (0.870,1.136) | (0.938,1.062) | ||
| Cmax | 1.282 | (1.150,1.414) | (0.938,1.062) | ||
| M8 | AUC0-12h | 1.086 | (0.923,1.249) | (0.938,1.062) | |
| AUCinf | 1.148 | (0.873,1.424) | (0.938,1.062) | ||
| Cmax | 1.167 | (1.019,1.315) | (0.938,1.062) | ||
| Multiple dose | Tunlametinib | AUCτ | 1.077 | (0.968,1.187) | (0.938,1.062) |
| Cmax | 1.113 | (0.936,1.289) | (0.938,1.062) | ||
| M8 | AUCτ | 1.203 | (1.023,1.383) | (0.938,1.062) | |
| Cmax | 1.150 | (0.990,1.310) | (0.938,1.062) |